Note: This document has been translated from the Japanese original for reference purposes only. In the event ofany discrepancy between this translated document and the Japanese original, the original shall prevail.

August 8, 2023
CompanyHeadquarters
Representative
Contact
Telephone
WebsiteTakara Bio Inc. (Securities code: 4974;
Prime Market)
Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, in chargeof PR & IR Department(+81)77-565-6970
https://www.takara-bio.co.jp/Notice Concerning Revisions to the First Half Financial Results Forecasts

Takara Bio Inc. hereby announces that in the light of the most recent operating trends, to revise the first half of thefinancial results forecasts for the fiscal year ending March 31, 2024 (April 1, 2023 – March 31, 2024), disclosed
on May 11, 2023, as described below.
1. Revisions to financial results forecasts
Revisions to consolidated financial results forecasts for the first half of the current fiscal year (April 1, 2023
through March 31, 2024)

Net sales

OperatingprofitOrdinaryprofit

Net income
attributable toowners ofthe parentNet income
per share

Million yen

Million yen

Million yen

Million yen

Yen

22,800

2,100

2,100

1,200

9.96

Revised forecasts (B)19,400

1,100

1,170

650

5.40

Change (B-A)(3,400)(1,000)

(930)

(550)

-

Change (%)(14.9)(47.6)(44.3)(45.8)-(Reference)
Actualconsolidated results
for the first half of theprevious fiscal year
(Fiscal year ended
March 31, 2023)

32,587

10,87010,955

8,538

70.91

Previously announced
forecasts (A)(Disclosed on May11, 2023)

(2) Reason for revision
Net sales are expected to be lower than the previously announced forecast due to sluggish sales of Reagents andInstruments overseas (U.S., China, and Europe), despite sales of CDMO and Gene Therapy to be mostly in linewith the previously announced forecast. Due to the decrease in sales, each profit item is expected to be lower
than the previous forecast. For this reason, the forecast of consolidated financial results for the first half of thefiscal year is revised.
Full-year forecasts remain unchanged due to the high composition of net sales and each profit item in thesecond half of the fiscal year.
For details of the forecasts announced this time, please refer to pages 10 of the "Consolidated Financial Results
for the Three Months Ended June 30, 2023 (Under Japanese GAAP)" announced today.

Forward-Looking Statements
Statements contained in these materials with respect to the Company’s current plans, forecasts, strategies and beliefs that are
not historical facts are forward-looking statements about the further performance of the Company and its consolidated
subsidiaries. These statements are based on management’s assumptions and beliefs in light of information currently available
to it, but are based on a number of assumptions and beliefs derived from information that contains significant risks anduncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could influence
actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well asexchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and productstrategies, declines in selling power of the Company’s existing and new products, disruptions to production, violations of ourintellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.